Results 101 to 110 of about 6,571 (189)

Pharmacokinetic and pharmacodynamic interaction of vildagliptin and voglibose in Japanese patients with type 2 diabetes

, 2013
Objective: To assess the extent of pharmacokinetic and pharmacodynamic interaction between vildagliptin, a potent and selective inhibitor of dipeptidyl peptidase IV (DPP-4) enzyme, and voglibose, an α-glucosidase inhibitor widely prescribed in Japan ...
Kenichi, Furihata, Nozaki, Sachiko, Saji, Takami, Kulmatycki, Kenneth, He, Yan-Ling, Yamaguchi, Masayuki, Sekiguchi, Kaneo   +6 more
core  

Absorption, metabolism, and excretion of [14C]vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans

, 2020
: The absorption, metabolism, and excretion of (1-[[3-hydroxy-1-adamantyl) amino] acetyl]-2-cyano-(S)-pyrrolidine (vildagliptin), an orally active and highly selective dipeptidyl peptidase 4 inhibitor developed for the treatment of type 2 diabetes, were ...
Hequn Yin, Lai Wang, Helen Gu, Volker Fischer, Heidi Einolf, Phi Tran, Yannick Batard, Dan Howard, Handan He, Harold Smith, James B Mangold   +10 more
core  

Bioequivalence and Food Effect Assessment for Vildagliptin/Metformin Fixed-dose Combination Tablets Relative to Free Combination of Vildagliptin and Metformin in Japanese Healthy Subjects

, 2015
Objective: To assess the bioequivalence of vildagliptin/metformin fixed-dose combination (FDC) tablets (50/250 mg and 50/500 mg) to free combinations of vildagliptin and metformin and the effect of food on the pharmacokinetics (PK) of vildagliptin and ...
Nozaki, Sachiko, Suzuki, Hikoe, Kulmatycki, Kenneth, Salunke, Atish Azad, He, Yan-Ling, Zhou, Wei, Chitnis, Shripad   +6 more
core  

Clinical evidence and mechanistic basis for vildagliptin's effect in combination with insulin

Vascular Health and Risk Management, 2013
Anja Schweizer,1 James E Foley,2 Wolfgang Kothny,2 Bo Ahrén31Novartis Pharma AG, Basel, Switzerland; 2Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA; 3Department of Clinical Sciences, Lund University, Lund, SwedenAbstract: Due to ...
Schweizer A, Foley JE, Kothny W, Ahrén B   +3 more
doaj  

Effects of DPP4 Inhibition on Inflammation and Oxidative Stress in Experimental Gestational Diabetes Mellitus. [PDF]

Int J Mol Sci
Tufan Akarslan Ö, Er A.
europepmc   +1 more source

Cost-Effectiveness Analysis of Triple Oral Antidiabetic Drug Combination in Patients With Type 2 Diabetes Mellitus: An Outpatient Study in Indonesia. [PDF]

J ASEAN Fed Endocr Soc
Hanifiyah IA, Nita Y, Libriansyah, Ridwan A, Achmad GNV.   +4 more
europepmc   +1 more source

In Silico Identification of Novel Leads as Potential DPP-IV Inhibitors as Antidiabetic Agents Using Virtual Screening. [PDF]

ACS Omega
Turkar MK, Ahirwar R, Sahu R, Bhadane R, Jain SK, Jain D.   +5 more
europepmc   +1 more source

Probable Vildagliptin-Associated Acute Pancreatitis in a Patient With Well-Controlled Type 2 Diabetes Mellitus: A Case Report. [PDF]

Cureus
Aung KZ, Saw NEL.
europepmc   +1 more source

EFFECT OF SITAGLIPTIN AND VILDAGLIPTIN ON WOUND HEALING IN MALE WISTAR RATS - AN EXPERIMENTAL STUDY

, 2018
Objective: Diabetes mellitus (DM) is a spectrum of common metabolic disorders, arising from a variety of pathogenic mechanisms. With an increasing incidence worldwide, DM will be likely a leading cause of morbidity and mortality in the future.
Kagal, Urmila, Timshetti, Somaling, Angadi, Netravathi B   +2 more
core  

Phosphatidylinositol-3-kinase/Protein Kinase B (PI3K/AKT) and Nucleotide-Binding Oligomerization Domain-like Receptor Family Pyrin Domain Containing 3 (NLRP3) Inflammasome Modulation Underlies the Neuroprotective Effects of Vildagliptin in a Rotenone-Induced Mouse Model of Parkinson's Disease. [PDF]

ACS Pharmacol Transl Sci
Patel D, Soni R, Bhogal I, Roy S, Shah J.   +4 more
europepmc   +1 more source